MA32356B1 - Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang - Google Patents

Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang

Info

Publication number
MA32356B1
MA32356B1 MA33319A MA33319A MA32356B1 MA 32356 B1 MA32356 B1 MA 32356B1 MA 33319 A MA33319 A MA 33319A MA 33319 A MA33319 A MA 33319A MA 32356 B1 MA32356 B1 MA 32356B1
Authority
MA
Morocco
Prior art keywords
dronedarone
blood
pharmaceutically acceptable
acceptable salt
medicament
Prior art date
Application number
MA33319A
Other languages
Arabic (ar)
English (en)
Inventor
Christophe Gaudin
Nacéra Hamdani
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40001356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32356B1 publication Critical patent/MA32356B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang.
MA33319A 2008-04-18 2010-11-03 Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang MA32356B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4599508P 2008-04-18 2008-04-18
FR0803525A FR2930150B1 (fr) 2008-06-24 2008-06-24 Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
PCT/IB2009/005605 WO2009144551A2 (fr) 2008-04-18 2009-04-16 Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d’un médicament permettant la régulation du niveau de potassium dans le sang

Publications (1)

Publication Number Publication Date
MA32356B1 true MA32356B1 (fr) 2011-06-01

Family

ID=40001356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33319A MA32356B1 (fr) 2008-04-18 2010-11-03 Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang

Country Status (26)

Country Link
US (1) US20110124724A1 (fr)
EP (1) EP2280702A2 (fr)
JP (1) JP2011518147A (fr)
KR (1) KR20100135814A (fr)
CN (1) CN102065857A (fr)
AR (1) AR072951A1 (fr)
AU (1) AU2009252898A1 (fr)
BR (1) BRPI0911198A2 (fr)
CA (1) CA2721491A1 (fr)
CL (1) CL2009000919A1 (fr)
CO (1) CO6260065A2 (fr)
CR (1) CR11734A (fr)
DO (1) DOP2010000300A (fr)
EA (1) EA201071209A1 (fr)
EC (1) ECSP10010553A (fr)
FR (1) FR2930150B1 (fr)
IL (1) IL208751A0 (fr)
MA (1) MA32356B1 (fr)
MX (1) MX2010011400A (fr)
NI (1) NI201000173A (fr)
PE (1) PE20091777A1 (fr)
SV (1) SV2010003701A (fr)
TW (1) TW200946108A (fr)
UY (1) UY31768A (fr)
WO (1) WO2009144551A2 (fr)
ZA (1) ZA201007391B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3195862A1 (fr) 2008-04-17 2017-07-26 Sanofi Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2013024411A1 (fr) 2011-08-12 2013-02-21 Lupin Limited Formulation cobroyée de dronédarone
IN2014KN02584A (fr) * 2012-05-22 2015-05-08 Sanofi Sa
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
JPWO2006016695A1 (ja) * 2004-08-10 2008-05-01 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
FR2930148A1 (fr) * 2008-04-17 2009-10-23 Sanofi Aventis Sa Utilisation de la dronedarone pour la preparation d'un medicament destine a la prevention de l'hospitalisation cardiovasculaire ou de la mortalite
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Also Published As

Publication number Publication date
CA2721491A1 (fr) 2009-12-03
FR2930150B1 (fr) 2011-01-14
EA201071209A1 (ru) 2011-04-29
AR072951A1 (es) 2010-10-06
MX2010011400A (es) 2010-11-12
BRPI0911198A2 (pt) 2015-10-13
AU2009252898A1 (en) 2009-12-03
JP2011518147A (ja) 2011-06-23
US20110124724A1 (en) 2011-05-26
KR20100135814A (ko) 2010-12-27
EP2280702A2 (fr) 2011-02-09
PE20091777A1 (es) 2009-12-04
IL208751A0 (en) 2010-12-30
NI201000173A (es) 2011-07-20
CR11734A (es) 2010-12-09
CN102065857A (zh) 2011-05-18
FR2930150A1 (fr) 2009-10-23
TW200946108A (en) 2009-11-16
DOP2010000300A (es) 2010-11-15
WO2009144551A3 (fr) 2010-01-14
UY31768A (es) 2009-12-14
ZA201007391B (en) 2012-01-25
CL2009000919A1 (es) 2010-04-09
WO2009144551A2 (fr) 2009-12-03
SV2010003701A (es) 2011-01-31
ECSP10010553A (es) 2010-11-30
CO6260065A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
MA32356B1 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2012177481A3 (fr) Inhibition du récepteur du facteur de croissance des fibroblastes pour le traitement de maladies
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
MA35716B1 (fr) Formulations pharmaceutiques
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
NO20092067L (no) 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander
EA201390618A1 (ru) Режимы дозирования при лечении офтальмологического сосудистого заболевания
MX2013006564A (es) Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
BR112018068170A2 (pt) ácido (2s,4r)-5-(5?-cloro-2?-fluor-[1,1?-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi-isoxazol-5-carboxamido)-2-metilpentanoico cristalino e usos dos mesmos
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112014006675A2 (pt) derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
UA114491C2 (uk) Фармацевтична композиція для попередження або лікування гіперліпідемії
Singh Nasal congestion and flushing: case report
WO2012108794A3 (fr) Dérivés de l'acide 1,2,4-triazol-з-yl-thioglycolique destinés à s'utiliser en thérapie